anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A Chinese medicinal composition for treating hyperlipidemia. At present, hypolipidemic drugs are generally adopted for treating hyperlipidemia, but some adverse reactions are easily caused. If etofibrate is used, upper abdominal fullness, pruritus and the like can be caused. The technical scheme of the invention is as follows: soaking processed rhizoma cyperi, costustoot, combined spicebush root, orange peel, green tangerine peel, immature bitter orange, officinal magnolia bark, villous amomum fruit, round cardamom, nardostachyos root-bark, citron bark, danshen root, szechuan lovage rhizome, peach seed, safflower, hiraute shiny bugleweed herb, turmeric root tuber, yanhusuo, trogopterus dung, frankincense, myrrh, lignum dalbergiae odoriferae, astragalus root, largehead atractylodes rhizome, manyflower solomonseal rhizome, cotton root, bidens tripartita, hawthorn, medicated leaven, malt, rice sprout, chicken's gizzard-membrane, rhubarb and raw liquorice in 1300 ml of water for 30 minutes, then decocting with slow fire, and filtering the decocted liquid. It has the advantages that: the medicine has stable therapeutic effect and is not easy to rebound. Meanwhile, the side effects caused by some existing medicines are avoided.
AIMS: This study aims to investigate the clinical practice of physicians working in obstetric setting toward postoperative nausea and vomiting (PONV) in parturients undergoing cesarean delivery (CD) with neuraxial anesthesia.
METHODS: We conducted this online survey to all active members of the Japan Society of Obstetric Anesthesiology and Perinatology (JSOAP), where leads academic society in obstetric anesthesia in Japan. The questionnaire was developed using the Delphi method. The survey included questions about routine practices for PONV prevention, the use of neuraxial opioids, optimal practices, and perceived obstacles. The email sent three times every 2 weeks as a reminder.
RESULTS: A total of 1046 e-mails were sent, and 307 JSOAP members responded to the survey (29.3%). More than half of responders (62.7%) used neuraxial opioids with intrathecal morphine being the most frequent. They had a higher rate of multimodal PONV prophylaxis compared with who did not use neuraxial opioids for postoperative analgesia (19.9% vs 6.7%). Metoclopramide was the commonest medication for PONV prevention, and there was a significant difference in the use of 5-hydroxytryptamine receptor antagonists (19.9% vs. 8.6%, p = 0.012). We observed that 80% of physicians reported the routine administration of prophylaxis for PONV for CD. Among these, 20% indicated the use of two or more agents. Conversely, in the cohort not administering neuraxial opioids, only 6.7% reported the use of two or more agents.
CONCLUSION: The online survey showed that the physicians using neuraxial opioids for CD had a higher proportion of multimodal PONV management involving two or more agents.
OBJECTIVES: Few studies have examined factors affecting steroid-free remission (SFR) in patients with immunoglobulin G4-related disease (IgG4-RD). The aim of this study was to investigate clinical factors affecting SFR in IgG4-RD.
METHODS: The medical records of 68 patients who met the 2020 revised comprehensive diagnostic criteria for IgG4-RD were reviewed retrospectively. SFR was defined as remission maintained for at least 6 months without corticosteroids. Cox regression analysis was performed to examine the associations between SFR and various clinical factors. The relapse rate after SFR was examined using the log-rank test.
RESULTS: After a median follow-up of 36 months, 30.9% (21/68) of patients with IgG4-RD achieved SFR. Multivariate Cox regression analysis revealed that IgG4-RD diagnosed by complete resection rather than by common diagnostic procedures was the only factor positively associated with SFR (hazard ratio, 7.41; 95% confidence interval, 2.23-24.60; P = .001). Furthermore, relapse after attainment of SFR was significantly less common in the group that underwent complete resection than in the group that did not undergo complete resection (log-rank P = .006).
CONCLUSIONS: Patients with IgG4-RD diagnosed by complete resection had a higher likelihood of achieving SFR and a lower rate of relapse after attaining SFR.
Anemia increases the risk of postoperative complications and mortality in patients undergoing coronary artery bypass grafting (CABG). In addition, the use of blood transfusions during cardiac surgery is associated with adverse effects and unfavorable outcomes. To reduce the need for transfusions and improve post-operative results, erythropoietin is used as part of Patient Blood Management (PBM). In anemic patients undergoing CABG, the use of Erythropoietin (EPO) can eliminate the need for blood components during and after surgery, as well as reduce adverse events and inflammation. The objectives of the proposed study are to reduce or eliminate the number of transfusions in the intraoperative and postoperative context by means of a Patient Blood Management (PBM) anemia treatment protocol for anemic patients who will undergo Coronary Artery Bypass Graft Surgery (CABG). The proposed study is a prospective, non-controlled interventional study to be carried out with anemic patients awaiting CABG surgery at Hospital São Paulo. There will be three groups of 40 participants each: Control Group (CG) of non-anemic individuals preoperatively; Non- PBM Group (NPBMG) of anemic individuals preoperatively and treated with blood components according to need; PBM Group (GPBM) of anemic individuals preoperatively and treated with EPO. The following parameters will be compared: length of postoperative hospital stay; mortality; postoperative cardiovascular events: clinical stroke, perioperative infarction, surgical reoperation due to bleeding; non- cardiovascular events: surgical site-associated infection and acute renal dysfunction; time in postoperative intensive care; time on mechanical ventilation; need for vasoactive drug use; inflammatory process and intra- and postoperative cardiac cell death. Confounding factors such as demographic and clinical parameters will be included in the analysis. It is expected that the GPBM will obtain the best results in relation to the GNPBM, similar to or better than the CG.
BACKGROUND: In this case series, a perioperative anticoagulation protocol for microvascular head and neck surgery in patients with thrombophilia is presented. Microvascular free-flap surgery is a standard procedure in head and neck surgery with high success rates. Nevertheless, flap loss-which is most often caused by thrombosis-can occur and has far-reaching consequences, such as functional impairment, prolonged hospitalization, and increased costs. The risk of flap loss owing to thrombosis is significantly increased in patients with thrombophilia. Therefore, perioperative anticoagulation is mandatory. To date, no perioperative anticoagulation protocol exists for these high-risk patients.
CASE PRESENTATION: We present three exemplary male Caucasian patients aged 53-57 years with free flap loss owing to an underlying, hidden thrombophilia.
CONCLUSION: We present a modified anticoagulation protocol for microvascular surgery in these high-risk patients, enabling successful microsurgical reconstruction.
A method implemented via a computing device. The method may include receiving, by the computing device, data associated with a subject having a neurodevelopmental disorder (NDD). The data associated with the subject may include demographic data, schooling data, family medical data, prior therapy data, observational assessment data, medication data, goals data, or combinations thereof. The method may further include evaluating, by the computing device, the data associated with the subject via a neurodevelopmental disorder treatment recommendation (NDDTR) model. The NDDTR model may evaluate the data associated with the subject to determine a therapy recommendation. The therapy recommendation may include a standard of care. The NDD may be ASD.
Prescribed dietary pattern. Carbohydrates from cellular sources, e.g., root vegetables, fruits, whole-grain rice, non-flour grain products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population similar to the acellular carbohydrate diet.
Deep venous thrombosis (DVT) has a significant negative impact on surgical and tumor patient's safety and quality of life. There was no specific report on the incidence and risk factors of postoperative lower extremity DVT in cervical cancer patients. Analysis of the risk factors of postoperative DVT in patients with cervical cancer is of great clinical significance for prevention and treatment. We retrospectively analyzed 309 cervical cancer patients treated by the Hubei Cervical Cancer Prevention Center and used a logistic regression model to test the risk variables of postoperative lower extremity deep venous thrombosis in cervical cancer patients. By univariate analyses, the results of the study showed that the incidence of postoperative DVT was significantly increased in cervical cancer patients complicated with old age, obesity, high preoperative plasma D-dimer level, increased preoperative triglyceride level, chronic diseases (hypertension, diabetes, and cardiovascular disease), open surgery, long operation time, intraoperative blood transfusion, advanced tumor stage, and preoperative chemotherapy/radiotherapy. Advanced age, obesity, elevated preoperative D-dimer level, high preoperative triglyceride level, and open surgery were independent risk factors for postoperative lower extremity DVT in patients with cervical cancer by multivariate regression analyses (all P < .05). In gynecologic patients with cervical cancer, there is a high incidence of postoperative lower extremity DVT. Clinicians should develop systematic and comprehensive prevention and treatment measures for the risk factors to lower this morbidity and improve patient prognosis.
Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 50mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans.
Patients with inflammatory arthritis will be compared to community-dwelling individuals from the 4th and 5th examination round from the Copenhagen City Heart Study (ClinicalTrials.gov identifier NCT02993172, I-Suite no. 03741, National Committee on Health Research Ethics approval HEH-2015-045).
Subjects randomized to this arm will be started on a lower dose of atorvastatin 40 mg daily for the first 4 weeks. If they are tolerating this dose without significant problems, atorvastatin will be increased to 80 mg daily.
Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC5, FDC6, FDC7 and FDC8, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDCs and reference formulations contains 10 mg ambrisentan and 40mg Tadalafil. OR Subjects will receive single dose of two FDCs from Part 1 in fed and fasted state. Each dosing period will be separated by 7 days wash out period.
The invention provides application of an inhibitor of deubiquitinase USP11 in preparation of a medicine for preventing or treating uric acid renal diseases. The inhibitor of the deubiquitinase USP11 is mitoxantrone. The uric acid nephropathy is nephritis or renal fibrosis. The invention also provides the application of the deubiquitinase USP11 as a biomarker for diagnosing the uric acid nephropathy. The invention confirms that the deubiquitinase USP11 plays a key role in occurrence and development of uric acid nephropathy, and proves that the mitoxantrone inhibitor can effectively relieve kidney injury caused by uric acid nephropathy, inhibit kidney fibrosis, improve kidney inflammation and protect kidney function. Compared with other existing medicines, mitoxantrone can block the onset and the progress of uric acid nephropathy from multiple aspects, and has obvious inhibition effect on the occurrence of renal fibrosis, so that the renal function is protected, and a theoretical basis is provided for clinically preparing mitoxantrone-related medicines for preventing and treating uric acid nephropathy.
The current study delineates a robust correlation between prefrontal cortex EEG signals and the psychological craving associated with methamphetamine usage. Dependents exhibit heightened β oscillation energy in the MPFC region and diminished γ oscillation energy across the DLPFC-MPFC region. Previously, through the implementation of rTMS interventions on the left DLPFC, the investigators have successfully reduced the craving levels in users when exposed to relevant cues, coupled with observed decreases in β oscillation energy and increases in γ oscillation energy in the MPFC region. This indicates that both β and γ oscillation energies are instrumental in representing the involvement of MPFC and DLPFC during craving episodes, and neuromodulatory technologies can modulate these energy levels, consequently reducing cravings. Furthermore, the investigators identified a significant augmentation in the theta energy in the occipital lobe when MA dependents are confronted with drug-related cue imagery, signifying a potential crucial neural marker for addiction-induced brain activity. Therefore, the investigators intend to employ the non-invasive continuous Theta-burst Stimulation (cTBS) , predicated upon biomarkers of addiction states, to administer specific frequency stimulations to targeted brain regions, aiming to achieve therapeutic objectives in addiction treatment.
A composition comprising xanthophyll carotenoid mesozeaxanthin (MZ) for use as a dietary supplement or food additive for oral consumption for improving the visual performance of a human subject, in particular, a human subject not experiencing age-related macular degeneration (AMD). Visual performance may be assessed by measuring one or more of spatial contrast sensitivity function, (best corrected) visual acuity, glare disability, discomfort glare, ocular straylight, photostress recovery and S-cone sensitivity. The composition may also comprise lutein and/or zeaxanthin. A preferred combination is MZ/lutein/zeaxanthin in the ratio 10:10:2. Additional components may include one or more vitamins and/or minerals; a vegetable oil, fish oil and/or omega 3 fatty acid. The composition may be in the form of an egg obtained from a hen fed with a feed comprising MZ. A method of preparing the composition comprising the step of mixing an effective amount of MZ with an acceptable dietary diluent, excipient or carrier is also claimed.
The pharmacokinetics of abiraterone were examined in subjects with baseline mild (N = 8) or moderate (N = 8) hepatic impairment (Child-Pugh Class A and B, respectively) and in 8 healthy control subjects with normal hepatic function. The systemic exposure (AUC) of abiraterone after a single oral 1,000 mg dose of abiraterone acetate increased by approximately 1.1-fold and 3.6-fold in subjects with mild and moderate baseline hepatic impairment, respectively compared to subjects with normal hepatic function.

In another trial, the pharmacokinetics of abiraterone were examined in subjects with baseline severe (N = 8) hepatic impairment (Child-Pugh Class C) and in 8 healthy control subjects with normal hepatic function. The systemic exposure (AUC) of abiraterone increased by approximately 7-fold and the fraction of free drug increased 2-fold in subjects with severe baseline hepatic impairment compared to subjects with normal hepatic function.

No dosage adjustment is necessary for patients with baseline mild hepatic impairment. In patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the recommended dose of abiraterone acetate to 250 mg once daily. Do not use abiraterone acetate in patients with baseline severe hepatic impairment (Child-Pugh Class C). If elevations in ALT or AST >5 x ULN or total bilirubin >3 x ULN occur in patients with baseline moderate hepatic impairment, discontinue abiraterone acetate treatment [see Dosage and Administration (2.4)and Clinical Pharmacology (12.3)] . 

For patients who develop hepatotoxicity during treatment, interruption of treatment and dosage adjustment may be required [see Dosage and Administration (2.4), Warnings and Precautions (5.3), and Clinical Pharmacology (12.3)].
OBJECTIVE: Previous research on patellar and trochlear groove osteochondritis dissecans (OCD) is limited by small sample sizes. This study aims to describe the presentation of patients with OCD lesions of the patella and trochlea and characterize the outcomes of operative and nonoperative treatments.
METHODS: This retrospective cohort study identified all patients from a single institution from 2008 to 2021 with patellar and/or trochlear OCD lesions. Patients were excluded from the study if surgical records were unavailable or if the patient had knee surgery for a different injury at index surgery or in the 12 months postoperative. Minimum follow-up was 12 months. Outcomes included a return to sports (RTS), pain resolution, radiographic healing, and treatment "success" (defined as full RTS, complete pain resolution, and full healing on imaging).
RESULTS: A total of 68 patients (75 knees) were included-45 (60%) with patellar OCD and 30 (40%) with trochlear. Of the patients, 69% were males. The median age at knee OCD diagnosis was 14 years. At the final follow-up, 62% of knees (n = 44) recovered sufficiently to allow a full RTS and 54% of knees (n = 39) had full pain resolution. Of the 46 knees with radiographic imaging at least 1 year apart, 63% had full healing of the lesion. There was no significant difference in RTS, pain resolution, radiographic healing, or overall success when comparing treatments.
CONCLUSIONS: This study provides valuable epidemiologic demographic and outcome data regarding the scarcely reported patellar and trochlear OCD. While over half of patients fully returned to sports and reported full pain resolution, a large proportion continued to experience symptoms over a year after presentation. Future research should aim to better define the treatment algorithms for these OCD subtypes.
LEVEL OF EVIDENCE: Level III.
Information for Patients: Advise the patient to read the FDA-approved patient labeling ( Patient Information). 

Pregnancy:Advise female patients of childbearing age about the consequences of exposure to valsartan and hydrochlorothiazide tablets during pregnancy. Discuss treatment options with women planning to become pregnant. Ask patients to report pregnancies to their physicians as soon as possible [see Warnings and Precautions (5.1), Use in Specific Populations (8.1)] . 

Lactation:Advise women not to breastfeed during treatment with valsartan and hydrochlorothiazide tablets [see Use in Specific Populations (8.2)] . 

Symptomatic Hypotension:Advise patients that lightheadedness can occur, especially during the first days of therapy, and that it should be reported to their healthcare provider. Tell patients that if syncope occurs, to discontinue valsartan and hydrochlorothiazide tablets until the physician has been consulted. Caution all patients that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope [see Warnings and Precautions (5.2)] . 

Potassium Supplements:Advise patients not to use salt substitutes without consulting their healthcare provider [see Drug Interactions (7)] . 

Non-Melanoma Skin Cancer:Instruct patients taking hydrochlorothiazide to protect skin from the sun and undergo regular skin cancer screening.
NEW MATERIAL:The compound of formula I (X and Y are H or 1-3C alkoxy; Z is 1-3C alkoxy). EXAMPLE:2-(3-Methoxy-phenylcarbamoyl)-2-(2,4-dimethoxyphenyl)acetic acid. USE:Useful as a drug or its synthetic intermediate. PREPARATION:The compound of formula I is produced by reacting an aniline derivative of formula II with a phenylmalonic acid monoester derivative of formula III (R is lower alkyl) in the presence of a dehydrative condensation agent (e.g. trimethylsilyl phosphite) at room temperature and removing the ester group of the product. Cyclization of the compound of formula I in the presence of a condensation agent gives a 3-phenyl-2-quinolone derivative of formula IV exhibiting osteogenesis promoting action and useful as a remedy for osteoporosis.
Enrolled patients will receive 40 mg of esomeprazole (two pills of 20 mg strength of esomeprazole) once daily before breakfast for the entire duration of TRT (including the weekends and any interim gap period) and for two weeks after completion of thoracic radiation therapy (TRT). TRT will be delivered as per the discretion of the treating physicians.
Group 3 innate lymphoid cells (ILC3s) are essential for both pathogen defense and tissue homeostasis in the intestine. Dysfunction of ILC3s could lead to increased susceptibility to intestinal inflammation. However, the precise mechanisms governing the maintenance of intestinal ILC3s are yet to be fully elucidated. Here, we demonstrated that ferroptosis is vital for regulating the survival of intestinal ILC3. Ferroptosis-related genes, including GPX4, a key regulator of ferroptosis, were found to be upregulated in intestinal mucosal ILC3s from ulcerative colitis patients. Deletion of GPX4 resulted in a decrease in NKp46+ILC3 cell numbers, impaired production of IL-22 and IL-17A, and exacerbated intestinal inflammation in a T cell-independent manner. Our mechanistic studies revealed that GPX4-mediated ferroptosis in NKp46+ILC3 cells was regulated by the LCN2-p38-ATF4-xCT signaling pathway. Mice lacking LCN2 in ILC3s or administration of a p38 pathway inhibitor exhibited similar phenotypes of ILC3 and colitis to those observed in GPX4 conditional knock-out mice. These observations provide novel insights into therapeutic strategies for intestinal inflammation by modulating ILC3 ferroptosis.
BACKGROUND: Using three-dimensional image analysis, we previously reported suppression of ossification progression following posterior fusion surgery for cervical ossification of the posterior longitudinal ligament (OPLL). Here, we aimed to evaluate the morphological changes in thoracic OPLL using three-dimensional analysis.
METHODS: Seventeen patients (eight males and nine females; mean age, 56.9 years) who underwent posterior decompression and fusion (PDF) for thoracic OPLL were included. We evaluated the OPLL volume using a novel analysis involving creating a three-dimensional model from computed tomography images to measure the volume accurately. Additionally, OPLL thickness, width, and length were measured on sagittal and axial computed tomography planes. We investigated the morphological changes in OPLL after PDF. Furthermore, patients were classified into reduced volume and increased volume groups and associated factors were compared.
RESULTS: The mean OPLL volume was 1,677 mm3 preoperatively and 1,705 mm3 at the final examination and did not significantly differ. Volume reduction was observed in 7 of 17 cases (41 %). Although OPLL width and length significantly increased postoperatively, OPLL thickness significantly reduced from 7.1 mm preoperatively to 6.5 mm postoperatively (all, p < 0.05). The annual thickness changes significantly differed (p <0.05) in the reduced volume group (-0.36 mm/year) compared to that in the increased volume group (-0.06 mm/year).
CONCLUSIONS: Thoracic OPLL after PDF becomes thinner in the anteroposterior direction but increases horizontally and craniocaudally. The reduction in OPLL thickness was related to a reduction in ossification volume. We believe that volume reduction in thoracic OPLL is influenced by pulsation of the dural sac.